Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib July 23, 2025
ALKAZAR Ph 3 Trial of Neladalkib for Patients with TKI-naïve ALK-positive NSCLC initiated July 23, 2025
Preliminary topline efficacy results from Ph 2 TRIFOUR trial of nadunolimab in advanced TNBC announced July 23, 2025
Regulatory Update on Clinical Development Plan for Muzastotug in MSS-CRC Announced Following Productive Type B (End of Ph 1) Meeting with FDA July 23, 2025
Elraglusib Clinical Program Advanced in Ewing Sarcoma After Positive Ph 1 Trial Demonstrates CRs and PRs in R/R Ewing Sarcoma July 23, 2025
Tagrisso + chemo demonstrated statistically significant and clinically meaningful improvement in OS in EGFR-mutated advanced lung cancer July 23, 2025
FDA issues CRL for Supplemental BLA for Columvi® (glofitamab-gxbm) + GemOx combo for R/R DLBCL patients not candidates for autoSCT July 23, 2025
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML July 23, 2025
First Patient Enrolled in Ph 3 AK112-312/HARMONi-GI6 Trial of Ivonescimab for 1L Metastatic CRC July 23, 2025
First patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) PD in patients with advanced solid tumors July 23, 2025
Dose Level 1 of ANGELICA TRIAL completed; Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Heme Malignancies July 23, 2025
All Primary Endpoints Met in Ph 2 Trial of SLS009 in R/R AML; FDA Guidance Received to Advance into 1L Therapy Study July 23, 2025
Positive Safety Results from Ph 2 Trial of ENV-105 in Advanced Prostate Cancer Announced July 23, 2025
Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with LGIR NMIBC Announced July 23, 2025
FDA ODAC voted against the overall benefit/risk profile of Blenrep (belantamab mafodotin-blmf) combo in R/R multiple myeloma July 23, 2025
ENHERTU + Pertuzumab Granted Breakthrough Therapy Designation in the US as 1L Therapy for Patients with HER2+ve Metastatic Breast Cancer July 23, 2025
